48P: Real-world evaluation of ipilimumab (Ipi)/nivolumab (Nivo) in combination with two cycles of chemotherapy in patients (pts) with programmed death-ligand (PD-L1) negative advanced non-small cell lung cancer (aNSCLC): Interim results of the RW-9LA study

IF 20.8 1区医学 Q1 ONCOLOGY Journal of Thoracic Oncology Pub Date : 2025-03-01 Epub Date: 2025-03-29 DOI:10.1016/S1556-0864(25)00243-6

L. Decoster , S. Vande Kerckhove , E. Ravoet , F. Vervenne , K. Vekens

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

48P: ipilimumab (Ipi)/nivolumab （Nivo）联合两个周期化疗在程序性死亡配体（PD-L1）阴性晚期非小细胞肺癌（aNSCLC）患者（pts）中的实际评估：RW-9LA研究的中期结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

期刊最新文献

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial. Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9^th Edition Staging Database. First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and PD-L1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial. Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients.